Need for joint relative effectiveness assessment in countries with limited HTA capacities
Zoltán Kaló
Professor of Health Economics at Center for Health Technology Assessment, Semmelweis University
Our policy viewpoint paper about the HTA system in Romania has finally been published.
In my opinion the most important generalizable conclusion is that HTA recommendations in other high income countries (with potentially confidential prices) cannot replace local cost-effectiveness analyses when judging the economic value of new health technologies in a lower income country.
On the other hand there is no point in redoing relative effectiveness assessment, when such study is available. Therefore, countries like Romania with limited HTA capacities would significantly benefit from joint clinical assessments coordinated at the EU level.
For a limited period our paper can be downloaded from here: https://www.sciencedirect.com/science/article/pii/S2211883719300784?dgcid=author
Head of Gastroenterology Unit, Buda Health Center, Budapest
4 年Congrats
Corporate Servicing Advisor at American Express (Bilingual)
4 年Wonderful paper Dr. Zoltan, thanks for sharing
Health policy, strategy, engagement, connector, health diplomacy, negotiation, patient advisor
4 年Excellent paper thank you for sharing congratulations Zoltán Kaló
Thanks Zoltán and colleagues for yet another contribution to the discourse. The findings resonate with many of the narratives from evolving value-based healthcare systems; the challenges of capacity and, delivery of interventions of value. I posit that an indigenous ?approach to such health policy initiative will be assuring of success in the long term, than always a desire to start from where more advanced healthcare systems are today (despite their ongoing challenges at defining value).